🔴✨SOUL trial: Illuminating pathways in chronic kidney disease 💡SOUL trial: (Semaglutide cardiOvascular oUtcomes triaL) 💡The design of the SOUL trial and the baseline clinical data of its participants 👇 💡SOUL is a randomized, double-blind, parallel-group,

🎯 Managing Genital Mycotic Infections and UTIs Among patients on SGLT2i : Expert Consensus - A Quick Guide Source: Gorgojo-Martínez et al A Multidisciplinary Expert Consensus. J. Clin. Med. 2024, 13, 6509. https:// https://t.co/MT21XkTRrK #Nephpearls #UTI #SGLT2i #mycotic

Ten tips to teach learners to love nephrology (and recruit the next generation) https://t.co/YrS6UZUUYz

Original Article: Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension (BaxHTN phase 3 trial) https://t.co/iRVxdmp7Ss Editorial: Aldosterone Synthase Inhibition for Hypertension https://t.co/qAx3z4Iy7s #ESCCongress | @escardio

A groundbreaking study from Wuhan University is turning everything we thought we knew about Parkinson’s disease upside down. Researchers now believe the disease may not start in the brain at all, but in the kidneys. The study found abnormal clusters of alpha-synuclein (α-Syn)

Occam's razor: "Diagnostician should assume a single cause for multiple symptoms." Hickam's dictum: "A man can have as many diseases as he damn well pleases."

If I remember this patient he presented with AKI (Acute Gastroenteritis) on CKD, in fact he had Uremic frost as well!

Researchers in @ScienceAdvances have developed a biohybrid microrobot based on picoeukaryotes, tiny planktonic organisms, that delivers drugs to the kidney in mice through autonomous navigation and deep tissue penetration. Learn more: https://t.co/rxyNkHXeOB

GLP-1 RA & Nutritional Deficiencies In a new study of 460k people on GLP-1 RA, it was shown that: 1️⃣ Vitamin D deficiency was most common (13.6%). 2️⃣ 12.7% developed nutritional deficiencies in 6 months. 3️⃣ 22.4% within 12 months. 4️⃣ 8% of people saw a dietitian within 6

Doctor Being a Lifelong Student! Lifelong learning is like watering and nurturing it. The more you cultivate it, the more it blooms with new ideas and skills! Do you Agree ?

🎯Meta analysis of 12 RCT 🌠 GLP-1 receptor agonists may slow kid- ney disease progression and lower the risk of heart disease, stroke, and death. 🌠 These findings suggest that GLP-1 receptor agonists offer multiple kidney and cardiovascular benefits to people with CKD

🎯 Unpacking UTI Risks: SGLT2i vs. GLP1ra and the Candida Connection ♦️SGLT2i exposure was associated with greater risk of candida UTI, but not noncandida UTI. ♦️SGLT2i to GLP1ra comparative risk of noncandida UTI did not differ in individuals with abnormal GU pathology

Combination therapy as a new standard of care in CKD - multiple trials testing new therapies in combo with SGLT2i - ARCTIC/PACIFIC trials: Baxdrostat/dapa vs. dapa - EASi-KIDNEY: Vicadrostat/empa vs. empa - ZENITH-HP: Zibotentan/dapa vs. dapa https://t.co/gxVrfEQDvs #ERA25

🎯 Hydrocortisone and Risk Factors for Kidney Replacement Therapy in Septic Shock ♦️ This is a post hoc analysis of the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) randomized clinical trial (RCT), a multicenter placebo-controlled

Telmisartan A "cardiometabolic sartan" is a specific type of angiotensin II receptor blocker (ARB) that, in addition to its primary function of lowering blood pressure, also exhibits beneficial effects on metabolic parameters, potentially making it useful in treating conditions

Comparative Effectiveness of GLP1-RA vs SGLT2i in Preventing Chronic Kidney Failure and Mortality in people with T2 diabetes & CKD SGLT2i more favourable for kidney outcomes https://t.co/3yVZ4oXIz8

Lorundrostat - an aldosterone synthase inhibitor Lorundrostat was associated with greater reductions in 24-hr average BP than placebo in pts with uncontrolled & treatment-resistant hypertension. K level >6.0 occurred in 5 pts (5%) in the stable-dose group https://t.co/uVP7GVwFVG

➡️ SOLO CKD Trial 🌟 Hyperphosphatemia (HP) is a common complication in an advanced stage of chronic kidney disease (CKD) and is associated with cardiovascular issues, metabolic bone abnormalities and worsening of secondary hyperparathyroidism. 🌟 This first real-world study

Sparsentan (DEARA) and FSGS #Nephpearls #NKFClinicals 📌 DUET (Phase 2) https://t.co/WoEn1erFhm 📌 DUET Posthoc https://t.co/hBxxXk1SoV 📌 DUPLEX (Phase 3) https://t.co/LyR3AGtmTV

🧵 Finerenone & Atrial Fibrillation Prevention 🫀💊 1/ Background 🏥 Mineralocorticoid receptor antagonists (MRAs) influence fibrosis & inflammation, which are linked to atrial fibrillation/flutter (AFF) risk. Could finerenone, a non-steroidal MRA, reduce new-onset AFF? Let’s

"World Kidney Day celebrations at MMCRI Superspeciality Hospital, alongside the Mysore Nephrology Association, highlight the importance of kidney health and encourage community engagement in preventative care." #WorldKidneyDay